Another phase II clinical study combined DC therapy loaded with tumor lysate or peptides (surviving, telomerase and p53) with consecutive IL-2 (2 million international units [mIUs]/day for 5 days) with metronomic cyclophosphamide (2 × 50 mg/day biweekly) and a Cox-2 inhibitor (200 mg daily) in melanoma patients.73 Here, TP53 is linked to melanoma.